Premium
Carbon ion radiotherapy for patients with hepatocellular carcinoma in the caudate lobe
Author(s) -
Okazaki Shohei,
Shibuya Kei,
Shiba Shintaro,
Okamoto Masahiko,
Miyasaka Yuhei,
Osu Naoto,
Kawashima Motohiro,
Kakizaki Satoru,
Araki Kenichiro,
Shirabe Ken,
Ohno Tatsuya
Publication year - 2021
Publication title -
hepatology research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.123
H-Index - 75
eISSN - 1872-034X
pISSN - 1386-6346
DOI - 10.1111/hepr.13606
Subject(s) - medicine , adverse effect , hepatocellular carcinoma , radiation therapy , carbon ion radiotherapy , gastroenterology , hepatic encephalopathy , surgery , radiology , cirrhosis
Aim The treatment of hepatocellular carcinoma in the caudate lobe (HCCCL) is technically challenging. We aimed to investigate the efficacy and toxicity of carbon ion radiotherapy (C‐ion RT) for HCCCL. Methods Patients with HCCCL treated with C‐ion RT at our hospital between January 2011 and December 2018 were evaluated. The total dose was 52.8 or 60 Gy (relative biological effectiveness) in four or 12 fractions depending on the distance between the tumor and the gastrointestinal tract. The survival outcome, the presence or absence of recurrence (local recurrence, intrahepatic recurrence outside the irradiation field, or extrahepatic recurrence), and acute/late adverse events were evaluated. Results Nine patients were included. The median tumor size was 3.4 cm, and the median follow‐up duration was 18.3 months for all patients. No patient developed local recurrence during follow‐up. Five patients subsequently developed intrahepatic recurrence outside the irradiation field and two had extrahepatic metastasis. Five patients died of hepatocellular carcinoma. No acute adverse events of grade ≥2 were observed. Two patients experienced grade 2 or 3 late adverse events, including obstructive jaundice, hepatic encephalopathy, ascites, and edema. Conclusion Carbon ion radiotherapy for HCCCL achieved excellent local control with acceptable adverse events and can thus be a curative treatment option for HCCCL.